Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
We aimed to analyze the risks of extrapyramidal symptoms (EPS) induced by typical and atypical antipsychotic drugs using a common pharmacokinetic-pharmacodynamic (PK-PD) model based on the receptor occupancy. We collected the data for EPS induced by atypical antipsychotics, risperidone, olanzapine and quetiapine, and a typical antipsychotic, haloperidol from literature and analyzed the following five indices of EPS, the ratio of patients obliged to take anticholinergic medication, the occurrence rates of plural extrapyramidal symptoms (more than one of tremor, dystonia, hypokinesia, akathisia, extrapyramidal syndrome, etc.), parkinsonism, akathisia, and extrapyramidal syndrome. We tested two models, i.e., a model incorporating endogenous dopamine release owing to 5-HT2A receptor inhibition and a model not considering the endogenous dopamine release, and used them to examine the relationship between the D2 receptor occupancy of endogenous dopamine and the extent of drug-induced EPS. The model incorporating endogenous dopamine release better described the relationship between the mean D2 receptor occupancy of endogenous dopamine and the extent of EPS than the other model, as assessed by the final sum of squares of residuals (final SS) and Akaike's Information Criteria (AIC). Furthermore, the former model could appropriately predict the risks of EPS induced by two other atypical antipsychotics, clozapine and ziprasidone, which were not incorporated into the model development. The developed model incorporating endogenous dopamine release owing to 5-HT2A receptor inhibition may be useful for the prediction of antipsychotics-induced EPS.
Department of Medico-Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Akiko
A
Matsui-Sakata
Hisakazu
H
Ohtani
Yasufumi
Y
Sawada
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D001569:Benzodiazepines / Q000009:adverse effects / Q000493:pharmacokinetics; D003024:Clozapine / Q000493:pharmacokinetics; D018849:Controlled Clinical Trials as Topic; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000493:pharmacokinetics; D006220:Haloperidol / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines / Q000493:pharmacokinetics; D000069348:Quetiapine Fumarate; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D018967:Risperidone / Q000009:adverse effects / Q000493:pharmacokinetics; D012559:Schizophrenia / Q000188:drug therapy; D013844:Thiazoles / Q000493:pharmacokinetics
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine